Skip to main content

Table 3 Diagnostic power of AFP to discriminate patients with HCC from patients with cirrhosis in different three staging systems

From: A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Classification

AUC

Sens%

Spe%

PPV%

NPV%

AC%

Number of nodules (n, %)

 Single (67, 43.2%)

0.71

22

100

100

53

58

 Multiple (88, 56.8)

0.74

31

100

100

52

60

Macrovascular invasion (n, %)

 Absent (141, 91%)

0.74

25

100

100

38

48

 Present (14, 9%)

0.65

50

100

100

90

91

Size of nodules (n, %)

 <2 (48, 31%)

0.72

13

100

100

63

65

 >2 (107, 69%)

0.75

33

100

100

49

59

BCLC stage (n, %)

 0-A (109, 70.3%)

0.71

19

100

100

41

48

 B (46, 29.7)

0.8

52

100

100

75

80

CLIP stage (n, %)

 0-1 (122, 79%)

0.69

17

100

100

39

45

 2-3 (33, 21%)

0.88

63

100

100

82

86

Okuda stage (n, %)

 Stage I (117, 75.5%)

0.67

23

100

100

41

50

 Stage II (38, 24.5%)

0.89

39

100

100

70

75